Secondary Hyperparathyroidism

Clinical Predictors of Post-PTx Hungry Bone Syndrome Identified

Publish Date September 24, 2021

Hungry bone syndrome occurs in 1 of 5 patients after parathyroidectomy for secondary hyperparathyroidism of renal origin, a study found.

Magnesium Supplementation May Improve CKD-MBD

Publish Date September 23, 2021

Magnesium homeostasis in CKD-MBD been the subject of increasing attention because it plays an important role in the pathophysiology of cardiovascular disease and bone health, according to investigators.

SHPT Drugs Tied With Better Survival in the HD Population With COVID-19

Publish Date September 22, 2021

Paricalcitol and/or calcimimetic use is associated with improved survival in patients with COVID-19 receiving maintenance hemodialysis, a study found.

Denosumab Improves Bone Disease in Kidney Transplant Recipients

Publish Date September 21, 2021

The medication inhibits bone resorption but is associated with prolonged elevation in PTH levels that require treatment.

Cinacalcet Does Not Up Risk for Severe Gastrointestinal Bleeding in Hemodialysis

Publish Date August 23, 2021

Study is the largest to explore this potential safety issue to date.

Dietary Advice for Secondary Hyperparathyroidism Prevention

Publish Date August 20, 2021

The review was based on 198 scientific references.

Study IDs Possible Relationship Between NGAL and CKD-MBD in Dialysis

Publish Date August 19, 2021

Neutrophil gelatinase-associated lipocalin (NGAL) is not only a biomarker of kidney injury but also a bone-derived factor involved in metabolism.

An Elderly Woman With Ulcers in Her Thighs

Publish Date August 16, 2021

Take the quiz on this clinical case: Which of the following is NOT associated with non-uremic calciphylaxis?

Pro-Inflammatory Diet Associated With Elevated Parathyroid Hormone Levels

Publish Date July 26, 2021

In a cross-sectional study, hyperparathyroidism occurred more frequently in adults with a diet of high vs low inflammatory potential.

Etelcalcetide Shows Efficacy in Clinical Practice

Publish Date July 23, 2021

Patients on hemodialysis who have secondary hyperparathyroidism experienced a 40% reduction in PTH levels over 12 months of etelcalcetide treatment, investigators reported.